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Abstract
Introduction: Blood-based assays to measure brain amyloid beta (Aβ) deposition are
an attractive alternative to the cerebrospinal fluid (CSF)–based assays currently used
in clinical settings. In this study, we examined different blood-based assays to measure
Aβ and how they compare among centers and assays.
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Methods: Aliquots from 81 plasma samples were distributed to 10 participating centers. Seven immunological assays and four mass-spectrometric methods were used to
measure plasma Aβ concentrations.
Results: Correlations were weak for Aβ42 while Aβ40 correlations were stronger. The
ratio Aβ42/Aβ40 did not improve the correlations and showed weak correlations.
Discussion: The poor correlations for Aβ42 in plasma might have several potential
explanations, such as the high levels of plasma proteins (compared to CSF), sensitivity to pre-analytical sample handling and specificity, and cross-reactivity of different
antibodies. Different methods might also measure different pools of plasma Aβ42. We,
however, hypothesize that greater correlations might be seen in future studies because
many of the methods have been refined during completion of this study.
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INTRODUCTION

matched CSF Aβ42 concentrations previously measured in the original
cohorts, to theoretically include samples with a wide range of plasma

In Alzheimer’s disease (AD), amyloid beta (Aβ) deposition in the brain

Aβ levels. Across the 10 participating centers (Table 1), seven immuno-

is detectable using the cerebrospinal fluid (CSF) biomarkers Aβ42 or

logical assays and four MS methods were used in this study. All meth-

Aβ42/40 ratio and by using amyloid positron emission tomography

ods measured Aβ40 and Aβ42 but varied in whether the full-length

(PET).1 Because CSF sampling is mainly performed at memory clinics

Aβ1-40 and Aβ1-42 forms were measured (for simplicity, the terms

and other specialized centers and amyloid PET is costly with limited

Aβ40 and Aβ42 are used throughout), and two methods also measured

availability, blood-based assays have long been an attractive alterna-

the APP669-711 form. Methods were compared using Passing-Bablok

tive, especially in the primary care setting. The ability to reliably dis-

regression8 and Spearman’s rank correlation coefficient (rs ).

tinguish AD dementia from controls using Aβ in plasma has until 2016
showed poor performance and partially conflicting results.2 However,
newly developed highly sensitive immunoassays, as well as mass spec-

3

RESULTS

trometry (MS) methods, have shown a better and higher concordance
of Aβ in plasma with Aβ-PET or CSF amyloid status.3–7
The aim of this study was to examine how different methods that

The correlations for pair-wise method comparison (Figure 1) for Aβ42
were generally weak to moderate with a median rs value of 0.24 and

measure plasma Aβ42 and Aβ40 levels compare, and whether results

highest rs value of 0.72. The correlations for Aβ40 were stronger with

correlate linearly. Ten centers participated in this study, which included

a median rs value of 0.67 and highest rs value of 0.89. Interestingly,

seven immunoassays and four MS methods, each analyzing aliquots of

using the ratio Aβ42/Aβ40 did not improve the correlations (Figure 2)

81 unique ethylenediaminetetraacetic acid (EDTA)–plasma samples.

and showed weak correlations (similar to Aβ42) with a median rs value
of 0.25 and highest rs value of 0.65. See supporting information for
full correlation plots between all methods for Aβ40, Aβ42, and the

2

METHODS

Aβ42/Aβ40 ratio.

Individual de-identified EDTA–plasma samples (n = 81) were measured
from the prospective and longitudinal Swedish BioFINDER (Biomark-

4

DISCUSSION

ers for Identifying Neurodegenerative Disorders Early and Reliably)
cohort (n = 48); the prospective University College London Dementia

The results in this multicenter study showed acceptable correlations

Research Centre CSF cohort (n = 24); and the Clinical Neurochemistry

for plasma Aβ40, while there were poor correlations for plasma Aβ42,

Laboratory at the Sahlgrenska University Hospital, Mölndal, Sweden

as well as for the Aβ42/Aβ40 ratio. The moderate correlations between

(n = 9). Varied sampling and processing procedures were used across

the MS assays support comparable measurements but correlations are

these centers, and for this study the samples were prepared in 250 μL

not ideal (generally < 0.7).

aliquots, so each underwent one freeze–thaw cycle prior to distribu-

The MagQu method, which uses one antibody to capture Aβ40 and

tion. These aliquots were kept at –80◦ C pending distribution to par-

Aβ42 and immunomagnetic reduction to quantify the protein, does not

ticipating centers. The plasma samples were selected based on known

correlate with the other methods, thus it may measure other forms of
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Technology
platform

Participating centers, assay platform, and measured Aβ species

Center
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F I G U R E 1 Amyloid beta (Aβ)1-40 (top), Aβ1-42 (middle), and Aβ1-42/Aβ1-40 (bottom) correlations (Spearman) between the different centers
and methods

F I G U R E 2 Examples of amyloid beta (Aβ)1-42/Aβ1-40 correlation plots between different centers. The solid line represents the
Passing-Bablok regression line and the dashed line denotes the unity line (y = x). See supporting information for complete set of plots for all centers
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with other Aß isoforms, sample dilution before analysis, additive,s and
pre-incubation procedures are other factors that might influence the

RESEARCH IN CONTEXT

sensitivities. In addition, Aβ42 concentrations are still at or close to
1. Systematic review: The authors reviewed the litera-

the lower limit of quantification of most methods in plasma samples,

ture using PubMed and conference presentations. While

which also may explain the higher correlations between assays for the

blood-based assays until recently have shown conflict-

more abundant Aβ40 compared to Aβ42. Furthermore, several stud-

ing results in the ability to distinguish Alzheimer’s dis-

ies reported similar findings comparing enzyme-linked immunosorbent

ease from controls compared to cerebrospinal fluid (CSF)

assays and Simoa platforms for plasma Aβ40 and Aβ42.7,14,15 Spear-

biomarker profiles (amyloid beta [Aβ] and tau) and amy-

man coefficients were 0.68 and 0.71 for, respectively, Aβ40 and Aβ42,

loid positron emission tomography (PET), newly devel-

which corroborates the findings in this article for the same assays.

oped methods to measure Aβ in plasma have shown

Since completion of this study, many of the methods have undergone

results with improved diagnostic performance for specific

additional refinement and new method comparison studies are under-

applications. Citations directly relevant to the included

way. We hypothesize that greater correlations will now be seen; if not,

assays and their contexts are cited.

an in-depth analysis of method differences will need to be undertaken.

2. Interpretation: The findings in this study show correlations among 11 methods that measured ethylene-
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